Page 2 of 9 – SEC Filing CUSIP No. 004225108 Page 2 of 9 Pages
1.
NAMES OF REPORTING PERSONS
Baker Bros. Advisors LP
2.
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ¨
(b) ¨
3.
SEC USE ONLY
4.
SOURCE OF FUNDS*
OO
5.
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ¨
6.
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH 7.
SOLE VOTING POWER: 25,878,893 (1)
8.
SHARED VOTING POWER: 0
9.
SOLE DISPOSITIVE POWER: 25,878,893 (1)
10.
SHARED DISPOSITIVE POWER: 0
11.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
25,878,893 (1)
12.
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* ¨
13.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
21.6% (1)(2)
14.
TYPE OF REPORTING PERSON*
IA, PN
(1) Includes 3,125 shares of the common stock of Acadia Pharmaceuticals, Inc. (the “Issuer”) underlying
options directly held by Julian C. Baker, a principal of Baker Bros. Advisors LP (“the Adviser”) and 56,000 shares
of the common stock of the Issuer underlying options directly held by Dr. Stephen R. Biggar, an employee of the Adviser.
(2) Based on 119,746,592 shares of the Issuer’s
common stock outstanding as of August 10, 2016, as reported in the Issuer’s Prospectus filed with the Securities Exchange
Comission (“SEC”) on August 10, 2016.
Follow Acadia Pharmaceuticals Inc (NASDAQ:ACAD)
Follow Acadia Pharmaceuticals Inc (NASDAQ:ACAD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
| CUSIP No. 004225108 | Page 2 of 9 Pages |
| 1. | NAMES OF REPORTING PERSONS Baker Bros. Advisors LP | ||
| 2. | CHECK (b) ¨ | ||
| 3. | SEC USE ONLY | ||
| 4. | SOURCE OF FUNDS* OO | ||
| 5. | CHECK | ||
| 6. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7. | SOLE VOTING POWER: 25,878,893 (1) | |
| 8. | SHARED VOTING POWER: 0 | ||
| 9. | SOLE DISPOSITIVE POWER: 25,878,893 (1) | ||
| 10. | SHARED DISPOSITIVE POWER: 0 | ||
| 11. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: | ||
| 12. | CHECK | ||
| 13. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 21.6% (1)(2) | ||
| 14. | TYPE OF REPORTING PERSON* IA, PN | ||
| (1) | Includes 3,125 shares of the common stock of Acadia Pharmaceuticals, Inc. (the “Issuer”) underlying options directly held by Julian C. Baker, a principal of Baker Bros. Advisors LP (“the Adviser”) and 56,000 shares of the common stock of the Issuer underlying options directly held by Dr. Stephen R. Biggar, an employee of the Adviser. |
| (2) | Based on 119,746,592 shares of the Issuer’s common stock outstanding as of August 10, 2016, as reported in the Issuer’s Prospectus filed with the Securities Exchange Comission (“SEC”) on August 10, 2016. |
